I think this is my first post here... Gave up posting on
I think this is my first post here... Gave up posting on IH and have really only lurked here for several months, but essentially read this right after refreshing my schwab investments pages way too many times per day....
I have invested a large chunk of my portfolio with cool blue. I can guarantee as well there is no intent to sell any shares. My only wish is that i would have invested even more with the cool blue. The way the s-3 reads is completely confusing. when i first saw the s-3 stuff a few months ago and it was first reported i was confused as to why cool blue was called "selling" . the whole report was really the filling of the purchase of the shares not "selling". I dont pretend to know all the sec stuff, but i do know there are plenty of people using it to confuse investors along with all the other cloud of bs thrown in the air that most here on Ihang are sick of refuting.
I feel like i was one of the first to refute and research the bs about NP history in college and with his divorce that was being spread after an SEC filing. That was my first foray into these boards after recently investing (and having arguments with the wife over putting so many eggs in one basket) and seeing the distortions and lies put on the boards. Shortly after that i discovered the crappy nature of IH after my clear facts and arguments were deleted. Now i only read IH to get a chuckle out of the stuff that just... posts. its laughable. Now some of my joy is seeing what snark i can reply occasionally and try to get it past the deleters.
3
CytoDyn Inc (CYDY) Stock Research Links
Scroll down for more posts ▼
Top 10 Most Recent News Articles
GORGIE Targets Taste Buds with Berry Burst Ever feel like you're missing out on that energy drink everyone seems to be raving about? Well, GORGIE's out there making some noise again, and this time it's got a new punchy player in the game: Berry Burst. It's not just another drink; it's shaking things up in the energy aisle with its exclusive launch at Target. Modern style...
Continue Reading
Shifting the Standard: MRI's Rise in SCLC Treatment Here's a twist that baffles the traditionalists—ditch the prophylactic cranial irradiation (PCI) and catch clearer days with MRI surveillance for small-cell lung cancer (SCLC). The latest international phase III MAVERICK trial might just redraw the lines on what's considered standard care in this relentless disease....
Continue Reading
The Game-Changing Results Innovation in pharmaceuticals sometimes feels like a waiting game, but when a fresh breakthrough like this rolls in, it lights up the whole landscape. Risvutatug rezetecan, or Ris-Rez for short, has shown promising potential in the fight against relapsed small-cell lung cancer (SCLC) that has progressed after platinum-based therapy. Survival...
Continue Reading
Dissecting the Nuances of the EVOKE-03/KEYNOTE-D46 Trial Every once in a while, we come across a trial that rattles cages in the research community. Today, it's the EVOKE-03/KEYNOTE-D46 trial, a collision of hope and hard-knock reality. This Phase 3 trial, which sought to explore the potential combo of sacituzumab govitecan (SG) and pembrolizumab on metastatic non-small...
Continue Reading
Rearranging the Consultancy Chessboard Piling onto the game of consultancy realignments, PwC just made a move reminiscent of playing strategy poker. They're tossing together PwC US and PwC India's advisory capabilities for a new joint venture. It’s like pushing two puzzle pieces to make a single colorful picture that stretches from the U.S. all the way to the...
Continue Reading
Understanding Homeowners Insurance: Beyond the Basics Most folks diving into homeownership for the first time get caught up in the whirlwind of price tags, loans, and knick-knacks for their new place. Meanwhile, the nitty-gritty of homeowners insurance often gets tossed to the side. But take it from a weary watchdog of financial storms—it’s those details in the policy...
Continue Reading
Noteworthy Developments in Small-Cell Lung Cancer Treatment Let's dive into a story straight from the world of small-cell lung cancer (SCLC) that doesn't take any prisoners. The antidote making waves is tambotatug pelitecan, or Tam-Peli for short, showcasing its might in the unrelenting fight against relapsed SCLC. The phase III TAISHAN-302 trial puts Tam-Peli...
Continue Reading
Regeneron’s Tight Spot: Legal Showdown Well, here we go again—Regeneron Pharmaceuticals (NASDAQ:REGN) is under some serious heat. If you're an investor who faced significant losses with this biotech juggernaut, remember that the clock’s ticking down to the wire. By tomorrow, September 14, 2026, you need to decide if you're going to throw your hat in the ring for...
Continue Reading
The High Stakes Reality for UWM Investors If there's one thing that's certain in this jittery world of investing, it's that losses have a way of waking you up. Right now, anyone tied up with UWM Holdings Corporation (NYSE: UWMC) shares needs to keep their wits about them; we're barreling toward an October 13, 2026 deadline for a class action lawsuit. The clock's ticking...
Continue Reading
The Future of Landscaping Unveiled Get this—PANDAG is set to shake things up at GaLaBau 2026 with their futuristic G1 autonomous mower. This isn't just another piece of lawn equipment; it's practically a tech marvel on wheels, weaving together LiDAR, AI Vision, RTK, and 4G tech to make it the ultimate multitasker for the landscaping industry. We're talking obstacle...
Continue Reading
Top 5 Most Recently Viewed Articles
BioXcel Therapeutics: Facing the Heat BioXcel Therapeutics Inc. (BTAI) is in the doghouse—its stock just hit a jaw-dropping 52-week low of $0.53. That's an eye-watering drop of over 80% in the last year. Investors are glued to their screens, weighing whether to grab some shares at rock-bottom prices or steer clear as BioXcel grapples with mounting obstacles. This sharp...
Continue Reading
Guidehouse Appoints Ron White as Chief Information Officer Advancing the firm's AI-led strategy with visionary leadership to drive business transformation and scalable innovation MCLEAN, Va. – Guidehouse, a global AI-led professional services firm, has recently appointed Ron White as its Chief Information Officer (CIO). With over 35 years of expertise in enterprise...
Continue Reading
Market Growth Driven by Consumer Demand Recent studies indicate that the chemicals market for cosmetics and toiletries is experiencing significant growth. The market is set to increase from $27.7 billion to an impressive $35 billion by the end of 2029. This momentum speaks volumes about the trends affecting consumer preferences and the investment patterns of leading...
Continue Reading
Understanding the Semler Scientific Investigation The Rosen Law Firm is actively investigating potential securities claims for investors of Semler Scientific, Inc. (NASDAQ: SMLR). This initiative addresses concerns regarding the possibility that the company may have provided significantly misleading information about its business practices to the public. Why You Should Be...
Continue Reading
Bitget Wallet Introduces Fomo Thursdays Events Bitget Wallet, a prominent non-custodial crypto wallet, is thrilled to announce the launch of its fourth Fomo Thursdays event, brought to life in collaboration with Velo Protocol. This event focuses on broadening participation in the crypto space, featuring a staggering prize pool of 3.47 million VELO tokens and 50,000 slots...
Continue Reading